Fujifilm invests in Suono Bio to advance inflammatory-mediated disease pipeline — 3 insights

Fujifilm Corp. invested an undisclosed amount in Suono Bio to support the company’s second-generation drug pipeline.

Advertisement

Here’s what you should know:

1. Suono Bio is developing a series of therapies to treat inflammatory diseases.

2. Boston-based Brigham and Women’s Hospital gastroenterologist Giovanni Traverso, MD, Polatis Partners Partner Amy Schulman and Carl Schoellhammer, PhD, founded the company.

3. Dr. Schoellhammer said, “I am thrilled that we have the opportunity to forge a long and fruitful relationship with Fujifilm to advance the development of our core technology. Their investment is a critical validation of our platform.”

More articles on gastroenterology:
Dr. David Kim pleads guilty to accepting $4.5M in kickbacks — 6 insights
ASC supply chain challenges & opportunities: 3 Qs with Cardinal Health’s Marvella Thomas
Possible new ASC one step closer after Louisiana city council passes ordinance

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.